Semaglutide
Product Information
It is not for human consumption. Use only in a laboratory setting by qualified personnel. The FDA has not evaluated this product for safety or efficacy. Any other use is strictly prohibited.
Semaglutide Specifications
A synthetic 31-residue analogue of human GLP-1(7-37) acting at the GLP-1 receptor, carrying a C18 fatty diacid chain associated with extended albumin binding.
Chemical Properties and Registry Information
| Property | Value |
| Name and synonyms | Semaglutide, NN9535, GLP-1(7-37) analogue |
| Material category | Synthetic GLP-1 receptor agonist peptide |
| Sequence | His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly (31 residues, free acid C-terminus) |
| Molecular formula | C187H291N45O59 |
| Average molecular mass | 4113.58 g/mol |
| CAS Registry Number | 910463-68-2 |
| PubChem CID | CID 56843331 |
| Structural features | An analogue of human GLP-1(7-37). In GLP-1 numbering: Ala8 is replaced by 2-aminoisobutyric acid (Aib), which resists dipeptidyl peptidase-4 cleavage; Lys34 is replaced by Arg; and Lys26 is acylated through a gamma-Glu-(AEEA)2 linker with octadecanedioic acid, a C18 fatty diacid associated with albumin binding. |
| Appearance | White to off-white lyophilized powder in sterile glass vial |
| Solubility | Soluble in water at neutral to slightly alkaline pH |
| Physical form | Catalogue vial; exact salt/counter-ion and excipients are batch-specific and must be verified in the CoA and SDS. |
Note: Registry values apply only to the specific molecular entity, sequence, termini, and material form. Batch records take precedence over family-level literature identifiers.
Research Background and Published Evidence
Published research
Semaglutide is used in GLP-1 receptor binding and signalling studies, in comparative incretin pharmacology, and in analytical-method development for acylated peptides, where the fatty-acid side chain is what separates it from unmodified GLP-1. Its design and preclinical characterisation were reported by Lau et al. [2]; clinical programmes have since been published under the SUSTAIN and STEP names [3].
Current scientific understanding
Receptor and clinical publications describe defined study systems and populations and do not establish safety, efficacy, or suitability for this catalogue batch. Regulatory classification and permitted supply vary by jurisdiction.
Technical Comparison
| Aspect | This catalogue material | Comparator |
| Identity | Catalogue semaglutide material, subject to exact-form batch confirmation | Exact semaglutide reference standard |
| Structural distinction | Salt, counter-ion, residual solvent and nominal peptide content remain batch-specific | Defined 31-residue acylated peptide without formulation excipients |
| Analytical implication | Confirm identity, acylation and net peptide content against a matching standard and CoA | Reference formula, mass, CAS and CID apply only to the matching free peptide |
Quality and Testing
Quality information is batch- and presentation-specific. Use only the report linked to the exact size and lot. A report listed for another size, lot, or similarly named material must not be treated as evidence for this product.
Chromatographic area purity, identity, net peptide or analyte content, water or counter-ion content, sterility, endotoxin, and elemental impurities are different measurements. One result does not establish the others. Only tests supported by a visible, matching report should be regarded as available.
Laboratory Handling and Storage
Store and handle only under the conditions stated on the product label, batch CoA, and SDS. Keep the container secured, correctly identified, and protected from contamination. Do not infer storage, solvent compatibility, or stability from a related compound.
Laboratory preparation, analytical-method selection, risk assessment, personal protective equipment, and waste disposal should follow the applicable SDS and the institution’s approved procedures.
Regulatory and Legal Status
Research-use notice: This material is supplied exclusively by Alma Research Labs for laboratory research by qualified professionals and is not intended for human or veterinary use. Purchasers are responsible for compliance with applicable local requirements.
Sources and References
PubChem. Semaglutide, CID 56843331.
Lau et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry (2015).
Wilding et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine (2021).
